DS
ADVM

DRW Securities’s Adverum Biotechnologies ADVM Stock Holding History

DRW Securities’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,010
Closed -$105K – 117
2019
Q1 		$105K Buy
+2,010
New +$81.3K ﹤0.01% 77
2018
Q3 		– Sell
-4,000
Closed -$212K – 49
2018
Q2 		$212K Buy
4,000
+1,500
+60% +$90.2K 0.01% 68
2018
Q1 		$145K Sell
2,500
-500
-17% -$31.1K 0.01% 136
2017
Q4 		$105K Buy
+3,000
New +$98.7K 0.01% 433

Other funds holding ADVM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

DRW Securities's ADVM Position: Q2 2019 in Review

DRW Securities sold out of Adverum Biotechnologies (ADVM) in Q2 2019, closing a stake of 2,010 shares — an estimated $105K sold.

DRW Securities first reported a position in ADVM in Q4 2017 and held it in 4 quarters. The position peaked at $212K in Q2 2018. 94 funds tracked by Wall St. Rank hold ADVM as of Q2 2019.

  • DRW Securities reported no remaining Adverum Biotechnologies position as of Q2 2019 after selling out during the quarter.
  • DRW Securities sold 2,010 Adverum Biotechnologies shares in Q2 2019, an estimated $105K.
  • DRW Securities first reported a position in Adverum Biotechnologies in Q4 2017 and held it in 4 quarters.
  • DRW Securities's Adverum Biotechnologies position peaked at $212K in Q2 2018.
  • 94 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2019.

Based on DRW Securities's 13F filing for Q2 2019, filed 14 Aug 2019.